The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,332.00
Bid: 12,344.00
Ask: 12,346.00
Change: 68.00 (0.55%)
Spread: 2.00 (0.016%)
Open: 12,268.00
High: 12,388.00
Low: 12,256.00
Prev. Close: 12,264.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

Wed, 27th Mar 2024 08:02

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

"Traders are confident in the upcoming rate cuts. Robust US growth doesn't scare as long as inflation continues to ease. And even the recent rise in inflation doesn't concern much as it is believed to be temporary," said Swissquote Bank analyst Ipek Ozkardeskaya.

"As such, the Fed is expected to cut rates in June for the first time."

The latest core personal consumption expenditures reading, the Fed's preferred inflation gauge, is released on Friday.

Investors also digested some industrial data from China. The yen, meanwhile, tumbled as it continues to struggle despite the Bank of Japan's historic rate hike last week.

In early corporate news, Diploma announced the GBP236 million proposed acquisition of aerospace specialty fasteners distributor Peerless Aerospace Fastener, while AstraZeneca announced two drug approvals in Japan.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: down 0.1% at 7,920.80

----------

Hang Seng: down 1.4% at 16,394.79

Nikkei 225: closed up 0.9% at 40,762.73

S&P/ASX 200: closed up 0.5% at 7,819.60

----------

DJIA: closed down 31.31 points, 0.1%, at 39,282.33

S&P 500: closed down 14.61 points, 0.3%, at 5,203.58

Nasdaq Composite: closed down 68.77 points, 0.4%, to 16,315.70

----------

EUR: down at USD1.0827 (USD1.0828)

GBP: up at USD1.2628 (USD1.2626)

USD: up at JPY151.70 (JPY151.50)

Gold: up at USD2,179.73 per ounce (USD2,176.17)

(Brent): down at USD84.78 a barrel (USD85.94)

(changes since previous London equities close)

----------

ECONOMICS

----------

Wednesday's key economic events still to come:

10:00 GMT eurozone consumer confidence

10:00 GMT eurozone economic sentiment index

14:30 GMT US EIA crude oil stocks

22:00 GMT US Federal Reserve Governor Christopher Waller speaks

----------

The regulator of the UK's oil and gas companies has said that they need to take action to set themselves on a path to reducing emissions and warned it could block developments if they did not take reasonable steps. The North Sea Transition Authority said that a plan it published on Wednesday highlights "the need for action across the board on production decarbonisation". It said that it would work with oil and gas developers, but if they did not take steps it thought necessary it might not approve their applications. Despite falls in recent years, the production of oil and gas in the UK contributes around 3% of the UK's total greenhouse gas emissions. That is not taking into account the emissions produced when that oil and gas is burnt. This comes partly from the energy that oil rigs and other operations use to transport staff and equipment, pump up oil and much else beside. But it also comes from practices such as venting or flaring – the process of either releasing unwanted gas into the atmosphere, or burning it on site without utilising the energy that it could produce.

----------

The yen hit a 34-year low against the dollar on Wednesday, just over a week after the Bank of Japan announced a much-anticipated interest rate hike in a shift away from years of ultra-loose monetary policy. The unit weakened to JPY151.97 per dollar, its softest since 1990, raising speculation that authorities will intervene in markets to prop up the currency. But its value soon recovered to levels of around JPY151.72. The drop came after a top central bank official suggested it would continue to pursue an accommodative policy for the time being, echoing previous comments from the BoJ.

----------

BROKER RATING CHANGES

----------

UBS raises Sainsbury's to 'buy' (neutral) - price target 295 (275) pence

----------

COMPANIES - FTSE 100

----------

Diploma announced the proposed acquisition of Peerless Aerospace Fastener, a distributor of specialty fasteners into the US and European aerospace markets, for around GBP236 million. The London-based supplier of specialised technical products and services said it expects the transaction to complete in the next few weeks, following customary regulatory clearances. Diploma Chief Executive Officer Johnny Thomson commented: "Peerless is an excellent acquisition for Diploma, aligned to our strategy of building high quality, scalable businesses for sustainable organic growth...We know and like the aerospace fasteners market and Peerless significantly extends our US capabilities and adds scale in Europe."

----------

AstraZeneca noted two drug approvals in Japan. In collaboration with Sanofi, the pharmaceutical firm's Beyfortus treatment was approved for the treatment of lower respiratory tract disease caused by respiratory syncytial virus in infants and children. AstraZeneca expects Beyfortus to be available for the upcoming 2024/25 RSV season, in line with existing Japanese guidelines. Meanwhile, its Truqap treatment in combination with Faslodex has also been approved in Japan for the treatment of adult patients with various forms of breast cancer after treatment with hormone therapy.

----------

COMPANIES - FTSE 250

----------

Playtech reported profit in 2023 more than doubled, and it said it has made a decent start to 2024. Playtech's pretax profit in 2023 jumped to EUR235.8 million from EUR95.6 million in 2022, as revenue rose 6.9% to EUR1.71 billion from EUR1.60 billion. The Isle of Man-based gambling software development company said its 2023 performance was ahead of expectations and that it is on track to meet its medium-term targets. It did not declare a dividend, unchanged from a year earlier. Chief Executive Officer Mor Weizer commented: "As well as delivering excellent financial results, the group made important strategic and operational progress, including our expansion across the US, opening a third Live Casino facility in Pennsylvania and taking the number of licences granted to 11 with further applications pending." Playtech said it has made a "solid" start to trading in 2024 and that it remains confident in executing on growth opportunities.

----------

OTHER COMPANIES

----------

S4 Capital reported a narrowed loss in 2023, though revenue fell as the company grappled with tough economic conditions and "client caution". S4 Capital's pretax loss in 2023 narrowed markedly to GBP13.9 million from GBP159.7 million in 2022, although revenue fell 5.7% to GBP1.01 billion from GBP1.07 billion, while total operating expenses fell 17% to GBP853.0 million from GBP1.03 billion. The London-based digital advertising, marketing and technology services firm also announced the appointment of Jean-Benoit Berty as chief operating officer, effective immediately. Executive Chair Martin Sorrell commented: "After our first four strong net revenue growth years, we had a difficult 2023 reflecting challenging global macroeconomic conditions, fears of recession and high interest rates. This resulted in client caution to commit and extended sales cycles, particularly for larger projects, a difficult year for new business, as well as spend reductions from some regional and smaller client relationships." Sorrell added that like-for-like net revenue for 2024 is to be down on 2023, "with a broadly similar overall level of profit performance to 2023". He added: "We remain confident that our talent, business model, strategy and scaled client relationships position us well for above average growth in the longer term, with an emphasis on deploying free cash flow to boost shareowner returns."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.